Phase I Study of Weekly Vinorelbine in Combination with Weekly Paclitaxel in Adult Patients with Advanced Refractory Cancer

References

• Canobbio L, Boccardo F, Pastorino G. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16(2 Suppl 4)33–36
   PubMed Web of Science ®Google Scholar
• Romanini A, Surbone A, Ricci S. Phase II study of continuous infusion vinorelbine (CIV) in patients with locally pretreated advanced head and neck cancer. Proc AACR 1993; 34: 205, abstract 1222
   Google Scholar
• Le Chevalier T, Brisgand D, Douillard J Y. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–367
   PubMed Web of Science ®Google Scholar
• Schiff P B, Fant J, Horwitz S B. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–667
   PubMed Web of Science ®Google Scholar
• Binet S, Fellous A, Lataste H. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989; 16(2 Suppl 4)5–8
   PubMed Web of Science ®Google Scholar
• McGuire W P, Rowinsky E K, Rosenshein N B. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–279
   PubMed Web of Science ®Google Scholar
• Fenelly D, Aghajanian C, Sharpiro F. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Oncol 1997; 15: 187–192
   Google Scholar
• Breier S, Lebedinsky C, Pelayes L. Preliminary analysis, weekly paclitaxel. Proc ASCO 1996; 15: 182, abstract 382
   Google Scholar
• Alvarez A, Mickiewicz E, Piris N. Weekly taxol high dose intensity (DI) treatment. Phase II study. Proc ASCO 1996; 15: 183, abstract 383
   Google Scholar
• Seidman A D, Murphy B, Hudis C. Activity of taxol by weekly 1 hour infusion in patients with metastatic breast cancer: a phase II and pharmacologic study. Proc ASCO 1997; 16: 148a, abstract 517
   Google Scholar
• Chang A, Hui L, Boros L. Phase I study of weekly one-hour paclitaxel treatment in advanced malignant disease. Proc ASCO 1997; 16: 16, abstract 817
   Google Scholar
• Abu-Rustum N, Aghajanian C, Barakat R. Salvage weekly paclitaxel (Taxol) for recurrent ovarian cancer. Proc ASCO 1997; 16: 364a, abstract 1296
   Google Scholar
• Burriss H A, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 1994; 21: 14–20
   Web of Science ®Google Scholar
• Weiselberg L, Budman D, O'Mara V. Phase I trial of sequential vinorelbine- paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc ASCO 1996; 15: 97, abstract 54
   Google Scholar
• Chang A Y, DeVore R, Johnson D. Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23: 19–21
   PubMed Web of Science ®Google Scholar
• Tortoriello A, Facchini G, Caponigro F. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998; 47: 91–97
   PubMed Web of Science ®Google Scholar
• Iaffaioli R V, Facchini G, Tortoriello A. Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 1997; 41: 86–90
   PubMed Web of Science ®Google Scholar
• Michelotti A, Gennari A, Salvadori B. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Ann Oncol 1996; 7: 857–860
   PubMed Web of Science ®Google Scholar
• Parimoo D, Jeffers S, Muggia F M. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996; 88: 1079–1080
   PubMed Web of Science ®Google Scholar
• Budman D, Weiselberg L, O'Mara V. Severe neurotoxicity in vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1997; 89: 87–88
   PubMed Web of Science ®Google Scholar
• Adams D. Synergy of vinorelbine-taxol combination treatment in two human breast cancer cell lines. Proc AACR 1994; 35: 327, abstract 1944
   Google Scholar
• Knick V C, Eberwein D J, Miller C G. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995; 87: 1072–1107
   PubMed Web of Science ®Google Scholar
• Budman D R, Calabro A, Stiel L. In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism or antagonism. Proc AACR 1996; 37, abstract 2493
   Google Scholar
• Carles G, Braguer D, Sabeur G. The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells. Anti-Cancer Drugs 1998; 9: 209–221
   PubMed Web of Science ®Google Scholar
• Photiou A, Shah P, Leong L K. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33: 463–470
   PubMed Web of Science ®Google Scholar
• De Souza P L, Myers C E. Synergy analysis of vinorelbine and paclitaxel in prostate cancer. Proc AACR 1998; 39: 586, abstract 3986
   Google Scholar
• Livingston R B, Ellis G K, Gralow J R. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395–1400
   PubMed Web of Science ®Google Scholar
• Weber B L, Vogel C, Jones S. Intravenous vinorelbine as a first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722–2730
   PubMed Web of Science ®Google Scholar
• Twelves C, Dobbs N, Curnow A. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994; 70: 990–993
   PubMed Web of Science ®Google Scholar
• Furuse K, Kubota K, Kawahara M. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994; 11: 385–391
   PubMed Web of Science ®Google Scholar
• Loeffler T M, Freund F W, Lipke J. Schedule and dose intensified paclitaxel (T) as weekly one hour infusion, evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc ASCO 1995; 14: 470, abstract 1522
   Google Scholar
• Akerly W, Glantz M, Choy H. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16: 153–158
   PubMed Web of Science ®Google Scholar
• Fety R, Vernillet L, Perrocheau G. Pharmacokinetic study of docetaxel (D) plus vinorelbine (V) combination as first line CT in patients with MBC. Proc AACR 1996; 37: 183, abstract 1250
   Google Scholar
• Miller C G, Knick V C, Eberwein D. Navelbine and paclitaxel combinations provide improved activity with reduced toxicity by an immune status dependent mechanisms. Proc AACR 1996; 37: 437–438, abstract 2989
   Google Scholar